I've just persuaded my neurologist to prescribe me some Valproic Acid. Surprisingly easy, but he'd just said no to Tysabri . Think he just wanted me out of the room .
Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy
A specific HDAC inhibitor is Valproic acid (VPA), which is a class I-selective HDAC inhibitor
with anticonvulsive (anti-seizure) effects and thus widespread clinical use in the treatment
of epilepsy. It is a drug that can easily pass the blood-brain barrier, a mechanism which is
hard to achieve in many neurological pharmaceuticals, and has been suggested to provide
neuroprotection both in laboratory tests (In vitro) and also in clinical trials within humans
Previous studies have denoted that within primary cultures of rat corticol neurons the
ABCD2 gene, as discussed in he previous section, was denoted to be responsive to VPA,
strongly up-regulating the gene.
VPA is rapidly metabolized in the liver of mice, so no preclinical studies have been denoted
in ALD mice (knock-out mice; ABCD1-/-
) models. Instead, as VPA has been previously
shown to act as an epileptic drug, a small clinical trial focusing on five X-ALD patients was
performed by Forcade et al. (2010). 40mg/kg VPA (trade name: Depakine) was
administered orally each day for six-months, without causing any denoted side-effects.
Although ABCD2 levels were only slightly increased, and the elevated concentrations of
VLCFAs were not corrected, it was denoted that oxidative damage completely normalized
by the end of the treatment. These results suggest that the drug induced antioxidant
effects in X-ALD patients, which therefore could be of benefit to patients, particularly those
In other news, I'm seeing an endocrinologist next week, then I'm getting botox injections and a Baclofen pump in January .